Compugen Ltd. (CGEN)Healthcare | Biotechnology | Holon, Israel | NasdaqCM
2.82 USD
-0.07
(-2.422%) ⇩
(April 17, 2026, 4 p.m.
EDT)
After hours: 2.83 +0.01 (0.355%) ⇧ (April 17, 2026, 4:40 p.m. EDT) Short-term: ★★★★☆ | Long-term: ★★★☆☆ | Dividends: ★☆☆☆☆ |
Hot Take | April 18, 2026, 11:50 p.m. EDT
Compugen is exhibiting classic 'strong buy' momentum on both fundamentals and sentiment. The stock has established strong momentum with a 62% gain over the 200-day average, supported by a massive ~45% revenue growth year-over-year and an exceptionally strong balance sheet ($145M cash, minimal debt). While insider selling and low valuation multiple (-8.4x Forward PE due to negative forward earnings) create noise, the underlying business turnaround is compelling. Speculative capital is clearly flowing in via options, targets remain at $13, and there is no immediate reversal signal. Hold for accumulation. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.122787 |
| MSTL | 0.123822 |
| AutoETS | 0.123993 |
| AutoARIMA | 0.123994 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 65% |
| H-stat | 1.63 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.402 |
| Excess Kurtosis | -0.22 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 2.881 |
| Revenue per Share | 0.779 |
| Market Cap | 267,815,792 |
| Trailing P/E | 7.42 |
| Forward P/E | -8.46 |
| Beta | 2.77 |
| Profit Margins | 48.57% |
| Website | https://cgen.com |
As of April 18, 2026, 11:50 p.m. EDT: Options flow indicates a strong bullish bias, with Call Open Interest (OI) concentrated heavily in ITM and ATM strikes (e.g., 2026-04-17 data shows 243 OI at $2.5 vs 243 at $7.5 OTM, but significant intraday volume at ATM). Conversely, Put OI is negligible to zero. Implied Volatility for Calls is extremely compressed (approx 0.56% - 1.0% depending on strike/expiration, likely representing daily variance or a data quirk indicating very low fear), whereas Put IV is elevated (11.88%). This disparity suggests speculators are positioning for upside continuation following the recent price run-up, while betting are nearly non-existent. The absence of significant put writing at downside strikes reinforces a one-sided bullish sentiment.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.0287769 |
| Address1 | Azrieli Center |
| Address2 | Building D 26 Harokmim Street |
| All Time High | 19.9 |
| All Time Low | 0.34 |
| Ask | 2.87 |
| Ask Size | 1 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 573,960 |
| Average Daily Volume3 Month | 322,522 |
| Average Volume | 322,522 |
| Average Volume10Days | 573,960 |
| Beta | 2.772 |
| Bid | 2.79 |
| Bid Size | 1 |
| Book Value | 1.086 |
| City | Holon |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Country | Israel |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 2.82 |
| Current Ratio | 6.558 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 2.92 |
| Day Low | 2.765 |
| Debt To Equity | 2.881 |
| Display Name | Compugen |
| Earnings Call Timestamp End | 1,772,458,200 |
| Earnings Call Timestamp Start | 1,772,458,200 |
| Earnings Timestamp | 1,772,458,200 |
| Earnings Timestamp End | 1,779,107,400 |
| Earnings Timestamp Start | 1,779,107,400 |
| Ebitda | 31,801,000 |
| Ebitda Margins | 0.43703997 |
| Enterprise To Ebitda | 3.898 |
| Enterprise To Revenue | 1.704 |
| Enterprise Value | 123,962,640 |
| Eps Current Year | -0.32667 |
| Eps Forward | -0.33333 |
| Eps Trailing Twelve Months | 0.38 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 972 3 765 8555 |
| Fifty Day Average | 2.101 |
| Fifty Day Average Change | 0.71899986 |
| Fifty Day Average Change Percent | 0.34221792 |
| Fifty Two Week Change Percent | 102.877686 |
| Fifty Two Week High | 2.94 |
| Fifty Two Week High Change | -0.120000124 |
| Fifty Two Week High Change Percent | -0.040816367 |
| Fifty Two Week Low | 1.23 |
| Fifty Two Week Low Change | 1.5899999 |
| Fifty Two Week Low Change Percent | 1.2926829 |
| Fifty Two Week Range | 1.23 - 2.94 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 966,000,600,000 |
| Float Shares | 92,414,367 |
| Forward Eps | -0.33333 |
| Forward P E | -8.460084 |
| Free Cashflow | 24,325,750 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 75 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.87286 |
| Gross Profits | 63,513,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.02081 |
| Held Percent Institutions | 0.13515 |
| Implied Shares Outstanding | 94,970,144 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ir Website | http://cgen.com/investors |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company's pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of PVRIG/PD-1 and PVRIG/TIGIT, as well as PVRIG/PD-1/TIGIT blockade; Bapotulimab, a therapeutic antibody targeting ILDR2 that is evaluated in Phase I clinical trials in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti- PD-1/TIGIT bispecific antibody, which is in Phase III clinical study in patients with advanced or metastatic non-small cell lung cancer. Its preclinical therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and Gilead Sciences, Inc. for the research, development, manufacturing, and commercialization of COM503 and other products. The company was incorporated in 1993 and is headquartered in Holon, Israel. |
| Long Name | Compugen Ltd. |
| Market | us_market |
| Market Cap | 267,815,792 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_166115 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | 35,343,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 270,782,625 |
| Number Of Analyst Opinions | 6 |
| Open | 2.91 |
| Operating Cashflow | 31,634,000 |
| Operating Margins | 0.83234 |
| Payout Ratio | 0.0 |
| Peg Ratio | 1.29 |
| Phone | 972 3 765 8585 |
| Post Market Change | 0.00999999 |
| Post Market Change Percent | 0.3546096 |
| Post Market Price | 2.83 |
| Post Market Time | 1,776,458,453 |
| Previous Close | 2.89 |
| Price Eps Current Year | -8.632565 |
| Price Hint | 4 |
| Price To Book | 2.5966852 |
| Price To Sales Trailing12 Months | 3.6806085 |
| Profit Margins | 0.48571998 |
| Quick Ratio | 6.459 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | -0.0700002 |
| Regular Market Change Percent | -2.42215 |
| Regular Market Day High | 2.92 |
| Regular Market Day Low | 2.765 |
| Regular Market Day Range | 2.765 - 2.92 |
| Regular Market Open | 2.91 |
| Regular Market Previous Close | 2.89 |
| Regular Market Price | 2.82 |
| Regular Market Time | 1,776,456,001 |
| Regular Market Volume | 659,274 |
| Return On Assets | 0.14419 |
| Return On Equity | 0.44839 |
| Revenue Growth | 44.773 |
| Revenue Per Share | 0.779 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 94,554,127 |
| Shares Percent Shares Out | 0.0099 |
| Shares Short | 936,019 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 1,064,062 |
| Short Name | Compugen Ltd. |
| Short Percent Of Float | 0.0099 |
| Short Ratio | 2.88 |
| Source Interval | 15 |
| Symbol | CGEN |
| Target High Price | 13.0 |
| Target Low Price | 4.0 |
| Target Mean Price | 5.83333 |
| Target Median Price | 4.0 |
| Total Cash | 145,640,000 |
| Total Cash Per Share | 1.54 |
| Total Debt | 2,960,000 |
| Total Revenue | 72,764,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 0.38 |
| Trailing P E | 7.4210525 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.7431 |
| Two Hundred Day Average Change | 1.0768999 |
| Two Hundred Day Average Change Percent | 0.61780727 |
| Type Disp | Equity |
| Volume | 659,274 |
| Website | https://cgen.com |
| Zip | 5,885,849 |